Regulation of endothelial nitric oxide synthase in pathophysiological conditions

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 11, Issue 2, 2011, Pages 109-118

  Isenović, Esma R ^a   Soskić, Sanja ^a   Düngen, Hans Dirk ^b   Dobutović, Branislava ^a   Elvis, Tahirović ^b   Simone, Inkrot ^b   Marche, Pierre ^c  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Institute OfCardiometabolism and Nutrition   (France)

Author keywords

Cardiovascular disease; Endothelial nitric oxide synthase; Insulin resistance; Type 2 diabetes mellitus

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; ENDOTHELIUM DERIVED CONSTRICTING FACTOR; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN; SUPEROXIDE; THROMBOPLASTIN; VASCULAR CELL ADHESION MOLECULE 1; INSULIN; NITRIC OXIDE;

APOPTOSIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAVEOLA; CELL PROLIFERATION; CELL SURVIVAL; DIABETIC ANGIOPATHY; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; ENZYME MODIFICATION; ENZYME REGULATION; GLYCOSYLATION; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE PERFUSION; HEART PROTECTION; HYPERTENSION; INSULIN BINDING; INSULIN RESISTANCE; ISCHEMIA; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION; VASODILATATION; VITAMIN SUPPLEMENTATION; DIABETES MELLITUS; HUMAN; METABOLISM; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS; ENDOTHELIUM, VASCULAR; HUMANS; INSULIN; INSULIN RESISTANCE; NITRIC OXIDE;

EID: 83455172348     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152911798346972     Document Type: Review

References (147)

1. Hayden, M.R.; Tyagi, S.C. Is type 2 diabetes mellitus a vascular disease (atheroscleropathy) with hyperglycemia a late manifestation? The role of NOS, NO, and redox stress. Cardiovasc. Diabetol., 2003, 2, 2.
2. Lowenstein, C.J.; Glatt, C.S.; Bredt, D.S.; Snyder, S.H. Cloned and expressed macrophage nitric oxide synthase contrasts with the brain enzyme. Proc. Natl. Acad. Sci. USA, 1992, 89, 6711-6715.
3. Nishida, K.; Harrison, D.G.; Navas, J.P.; Fisher, A.A.; Dockery, S.P.; Uematsu, M.; Nerem, R.M.; Alexander, R.W.; Murphy, T.J. Molecular cloning and characterization of the constitutive bovine aortic endothelial cell nitric oxide synthase. J. Clin. Invest., 1992, 90, 2092-2096.
4. Ding, H.; Triggle, C.R. Endothelial dysfunction in diabetes: multiple targets for treatment. Pflugers Arch., 2010, 459, 977-994.
5. Yu, Q.; Gao, F.; Ma, X.L. Insulin says NO to cardiovascular disease. Cardiovasc. Res., 2011, 89, 516-524.
6. Kolluru, G.K.; Siamwala, J.H.; Chatterjee, S. eNOS phosphorylation in health and disease. Biochimie, 2010, 92, 1186-1198.
7. Chatterjee, A.; Black, S.M.; Catravas, J.D. Endothelial nitric oxide (NO) and its pathophysiologic regulation. Vascul. Pharmacol., 2008, 49, 134-140.
8. Huang, P.L. eNOS, metabolic syndrome and cardiovascular disease. Trends Endocrinol. Metab., 2009, 20, 295-302.
9. Lefer, D.J.; Jones, S.P.; Girod, W.G.; Baines, A.; Grisham, M.B.; Cockrell, A.S.; Huang, P.L.; Scalia, R. Leukocyte-endothelial cell interactions in nitric oxide synthase-deficient mice. Am. J. Physiol., 1999, 276, H1943-1950.
10. Marletta, M.A. Nitric oxide synthase: aspects concerning structure and catalysis. Cell, 1994, 78, 927-930.
11. Fleming, I.; Bauersachs, J.; Fisslthaler, B.; Busse, R. Ca2+-independent activation of the endothelial nitric oxide synthase in response to tyrosine phosphatase inhibitors and fluid shear stress. Circ. Res., 1998, 82, 686-695.
12. Kuchan, M.J.; Frangos, J.A. Role of calcium and calmodulin in flow-induced nitric oxide production in endothelial cells. Am. J. Physiol., 1994, 266, C628-636.
13. Isenovic, E.R.; Divald, A.; Milivojevic, N.; Grgurevic, T.; Fisher, S.E.; Sowers, J.R. Interactive effects of insulin-like growth factor-1 and beta-estradiol on endothelial nitric oxide synthase activity in rat aortic endothelial cells. Metabolism, 2003, 52, 482-487.
14. Mombouli, J.V.; Vanhoutte, P.M. Kinins and endothelial control of vascular smooth muscle. Annu. Rev. Pharmacol. Toxicol., 1995, 35, 679-705.
15. Fleming, I.; Busse, R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2003, 284, R1-12.
16. Jagnandan, D.; Sessa, W.C.; Fulton, D. Intracellular location regulates calcium-calmodulin-dependent activation of organellerestricted eNOS. Am. J. Physiol. Cell Physiol., 2005, 289, C1024-1033.
17. Ayajiki, K.; Kindermann, M.; Hecker, M.; Fleming, I.; Busse, R. Intracellular pH and tyrosine phosphorylation but not calcium determine shear stress-induced nitric oxide production in native endothelial cells. Circ. Res., 1996, 78, 750-758.
18. Fleming, I.; Bauersachs, J.; Busse, R. Calcium-dependent and calcium-independent activation of the endothelial NO synthase. J. Vasc. Res., 1997, 34, 165-174.
19. Mulsch, A.; Bassenge, E.; Busse, R. Nitric oxide synthesis in endothelial cytosol: evidence for a calcium-dependent and a calcium-independent mechanism. Naunyn. Schmiedebergs Arch Pharmacol., 1989, 340, 767-770.
20. Isenovic, E.; Muniyappa, R.; Milivojevic, N.; Rao, Y.; Sowers, J.R. Role of PI3-kinase in isoproterenol and IGF-1 induced ecNOS activity. Biochem. Biophys. Res. Commun., 2001, 285, 954-958.
21. Corson, M.A.; James, N.L.; Latta, S.E.; Nerem, R.M.; Berk, B.C.; Harrison, D.G. Phosphorylation of endothelial nitric oxide synthase in response to fluid shear stress. Circ. Res., 1996, 79, 984-991.
22. Gallis, B.; Corthals, G.L.; Goodlett, D.R.; Ueba, H.; Kim, F.; Presnell, S.R.; Figeys, D.; Harrison, D.G.; Berk, B.C.; Aebersold, R.; Corson, M.A. Identification of flow-dependent endothelial nitric-oxide synthase phosphorylation sites by mass spectrometry and regulation of phosphorylation and nitric oxide production by the phosphatidylinositol 3-kinase inhibitor LY294002. J. Biol. Chem., 1999, 274, 30101-30108.
23. Garcia-Cardena, G.; Fan, R.; Stern, D.F.; Liu, J.; Sessa, W.C. Endothelial nitric oxide synthase is regulated by tyrosine phosphorylation and interacts with caveolin-1. J. Biol. Chem., 1996, 271, 27237-27240.
24. Michel, T.; Li, G.K.; Busconi, L. Phosphorylation and subcellular translocation of endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. USA, 1993, 90, 6252-6256.
25. Butt, E.; Bernhardt, M.; Smolenski, A.; Kotsonis, P.; Frohlich, L.G.; Sickmann, A.; Meyer, H.E.; Lohmann, S.M.; Schmidt, H.H. Endothelial nitric-oxide synthase (type III) is activated and becomes calcium independent upon phosphorylation by cyclic nucleotide-dependent protein kinases. J. Biol. Chem., 2000, 275, 5179-5187.
26. Chen, Z.P.; Mitchelhill, K.I.; Michell, B.J.; Stapleton, D.; Rodriguez-Crespo, I.; Witters, L.A.; Power, D. A.; Ortiz de Montellano, P.R.; Kemp, B.E. AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett, 1999, 443, 285-289.
27. Fleming, I.; Fisslthaler, B.; Dimmeler, S.; Kemp, B.E.; Busse, R. Phosphorylation of Thr(495) regulates Ca(2+)/calmodulindependent endothelial nitric oxide synthase activity. Circ. Res., 2001, 88, E68-75.
28. Michell, B.J.; Griffiths, J.E.; Mitchelhill, K.I.; Rodriguez-Crespo, I.; Tiganis, T.; Bozinovski, S.; de Montellano, P.R.; Kemp, B.E.; Pearson, R.B. The Akt kinase signals directly to endothelial nitric oxide synthase. Curr Biol, 1999, 9, 845-848.
29. Fulton, D.; Gratton, J.P.; Sessa, W.C. Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough? J. Pharmacol. Exp. Ther., 2001, 299, 818-824.
30. Harris, M.B.; Ju, H.; Venema, V.J.; Liang, H.; Zou, R.; Michell, B.J.; Chen, Z.P.; Kemp, B.E.; Venema, R. C. Reciprocal phosphorylation and regulation of endothelial nitric-oxide synthase in response to bradykinin stimulation. J. Biol. Chem., 2001, 276, 16587-16591.
31. Kou, R.; Greif, D.; Michel, T. Dephosphorylation of endothelial nitric-oxide synthase by vascular endothelial growth factor. Implications for the vascular responses to cyclosporin A. J. Biol. Chem., 2002, 277, 29669-29673.
32. Michell, B.J.; Chen, Z.; Tiganis, T.; Stapleton, D.; Katsis, F.; Power, D.A.; Sim, A.T.; Kemp, B.E. Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase. J. Biol. Chem., 2001, 276, 17625-17628.
33. Dimmeler, S.; Fleming, I.; Fisslthaler, B.; Hermann, C.; Busse, R.; Zeiher, A.M. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature, 1999, 399, 601-605.
34. Fulton, D.; Gratton, J.P.; McCabe, T.J.; Fontana, J.; Fujio, Y.; Walsh, K.; Franke, T.F.; Papapetropoulos, A.; Sessa, W. C. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature, 1999, 399, 597-601.
35. Koricanac, G.; Tepavcevic, S.; Zakula, Z.; Milosavljevic, T.; Stojiljkovic, M.; Isenovic, E.R. Interference between insulin and estradiol signaling pathways in the regulation of cardiac eNOS and Na(+)/K(+)-ATPase. Eur. J. Pharmacol., 2011, 655, 23-30.
36. Chen, H.; Montagnani, M.; Funahashi, T.; Shimomura, I.; Quon, M.J. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J. Biol. Chem., 2003, 278, 45021-45026.
37. Duran, W. N.; Seyama, A.; Yoshimura, K.; Gonzalez, D.R.; Jara, P.I.; Figueroa, X.F.; Boric, M.P. Stimulation of NO production and of eNOS phosphorylation in the microcirculation in vivo. Microvasc. Res., 2000, 60, 104-111.
38. Michell, B.J.; Harris, M.B.; Chen, Z.P.; Ju, H.; Venema, V.J.; Blackstone, M.A.; Huang, W.; Venema, R. C.; Kemp, B.E. Identification of regulatory sites of phosphorylation of the bovine endothelial nitric-oxide synthase at serine 617 and serine 635. J. Biol. Chem., 2002, 277, 42344-42351.
39. Garcia-Cardena, G.; Martasek, P.; Masters, B.S.; Skidd, P.M.; Couet, J.; Li, S.; Lisanti, M.P.; Sessa, W.C. Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the nos caveolin binding domain in vivo. J. Biol. Chem., 1997, 272, 25437-25440.
40. Sessa, W.C.; Garcia-Cardena, G.; Liu, J.; Keh, A.; Pollock, J.S.; Bradley, J.; Thiru, S.; Braverman, I.M.; Desai, K.M. The Golgi association of endothelial nitric oxide synthase is necessary for the efficient synthesis of nitric oxide. J. Biol. Chem., 1995, 270, 17641-17644.
41. Shaul, P.W.; Smart, E.J.; Robinson, L.J.; German, Z.; Yuhanna, I.S.; Ying, Y.; Anderson, R.G.; Michel, T. Acylation targets emdothelial nitric-oxide synthase to plasmalemmal caveolae. J. Biol. Chem., 1996, 271, 6518-6522.
42. Hecker, M.; Mulsch, A.; Bassenge, E.; Forstermann, U.; Busse, R. Subcellular localization and characterization of nitric oxide synthase(s) in endothelial cells: physiological implications. Biochem. J., 1994, 299(Pt 1), 247-252.
43. Chen, C.A.; Lin, C.H.; Druhan, L.J.; Wang, T.Y.; Chen, Y.R.; Zweier, J.L. Superoxide induces eNOS protein Thiyl radical formation: a novel mechanism regulating eNOS function and coupling. J. Biol. Chem., 2011.
44. Forstermann, U. Janus-faced role of endothelial NO synthase in vascular disease: uncoupling of oxygen reduction from NO synthesis and its pharmacological reversal. Biol. Chem., 2006, 387, 1521-1533.
45. Muscoli, C.; Cuzzocrea, S.; Riley, D.P.; Zweier, J.L.; Thiemermann, C.; Wang, Z.Q.; Salvemini, D. On the selectivity of superoxide dismutase mimetics and its importance in pharmacological studies. Br. J. Pharmacol., 2003, 140, 445-460.
46. Dumitrescu, C.; Biondi, R.; Xia, Y.; Cardounel, A.J.; Druhan, L.J.; Ambrosio, G.; Zweier, J.L. Myocardial ischemia results in tetrahydrobiopterin (BH4) oxidation with impaired endothelial function ameliorated by BH4. Proc. Natl. Acad. Sci. USA, 2007, 104, 15081-15086.
47. Chen, C.A.; Wang, T.Y.; Varadharaj, S.; Reyes, L.A.; Hemann, C.; Talukder, M.A.; Chen, Y.R.; Druhan, L. J.; Zweier, J. L. Sglutathionylation uncouples eNOS and regulates its cellular and vascular function. Nature, 2010, 468, 1115-1118.
48. Chen, C.-A.; Druhan, L.J.; Varadharaj, S.; Chen, Y.-R.; Zweier, J.L. Abstract 221: Phosphorylation and L-Arginine Increase Superoxide Generation from Endothelial Nitric Oxide Synthase (eNOS). Circulation, 2008, 118, S273.
49. Chen, C.-A.; Wang, T.-Y.; Varadharaj, S.; Reyes, L.; Talukder, M.A.H.; Chen, Y.-R.; Druhan, L.J.; Zweier, J.L. Abstract 5208: Sglutathiolation Uncouples Endothelial Nitric Oxide Synthase: A Novel Mechanism of Redox Signaling and Vascular Regulation. Circulation, 2009, 120, S1070.
50. Abel, E.D. Insulin signaling in heart muscle: lessons from genetically engineered mouse models. Curr. Hypertens. Rep., 2004, 6, 416-423.
51. Das, U.N. Insulin: an endogenous cardioprotector. Curr. Opin. Crit. Care, 2003, 9, 375-383.
52. Lundberg, J.O.; Gladwin, M.T.; Ahluwalia, A.; Benjamin, N.; Bryan, N.S.; Butler, A.; Cabrales, P.; Fago, A.; Feelisch, M.; Ford, P.C.; Freeman, B.A.; Frenneaux, M.; Friedman, J.; Kelm, M.; Kevil, C.G.; Kim-Shapiro, D.B.; Kozlov, A.V.; Lancaster, J.R., Jr.; Lefer, D.J.; McColl, K.; McCurry, K.; Patel, R.P.; Petersson, J.; Rassaf, T.; Reutov, V.P.; Richter-Addo, G.B.; Schechter, A.; Shiva, S.; Tsuchiya, K.; van Faassen, E.E.; Webb, A.J.; Zuckerbraun, B.S.; Zweier, J.L.; Weitzberg, E. Nitrate and nitrite in biology, nutrition and therapeutics. Nat. Chem. Biol., 2009, 5, 865-869.
53. SUDAR; Emina; DOBUTOVIC; Branislava; MILOSAVLJEVIC; Tijana; PUTNIKOVIC; Biljana; GLUVIC; Zoran; ISENOVIC; R., E. Interactive Effects of Insulin and β-Estradiol on Protein Kinase B Phosphorylation in Adult Rat Cardiomyocytes. English, 2009, 56, 723-728.
54. Gao, F.; Gao, E.; Yue, T.L.; Ohlstein, E.H.; Lopez, B.L.; Christopher, T.A.; Ma, X.L. Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: the roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation, 2002, 105, 1497-1502.
55. Montagnani, M.; Chen, H.; Barr, V.A.; Quon, M.J. Insulinstimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179). J. Biol. Chem., 2001, 276, 30392-30398.
56. Zeng, G.; Nystrom, F.H.; Ravichandran, L.V.; Cong, L.N.; Kirby, M.; Mostowski, H.; Quon, M.J. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation, 2000, 101, 1539-1545.
57. Zeng, G.; Quon, M.J. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J. Clin. Invest., 1996, 98, 894-898.
58. Abel, E.D. Myocardial insulin resistance and cardiac complications of diabetes. Curr. Drug Targets Immune Endocr. Metabol. Disord., 2005, 5, 219-226.
59. Coats, A.J.; Anker, S.D. Insulin resistance in chronic heart failure. J. Cardiovasc. Pharmacol., 2000, 35, S9-14.
60. Li, Q.X.; Xiong, Z.Y.; Hu, B.P.; Tian, Z.J.; Zhang, H.F.; Gou, W.Y.; Wang, H.C.; Gao, F.; Zhang, Q.J. Aging-associated insulin resistance predisposes to hypertension and its reversal by exercise: the role of vascular vasorelaxation to insulin. Basic Res. Cardiol., 2009, 104, 269-284.
61. Zhang, Q.J.; Li, Q.X.; Zhang, H.F.; Zhang, K.R.; Guo, W.Y.; Wang, H.C.; Zhou, Z.; Cheng, H.P.; Ren, J.; Gao, F. Swim training sensitizes myocardial response to insulin: role of Akt-dependent eNOS activation. Cardiovasc. Res., 2007, 75, 369-380.
62. Triggle, C.R.; Ding, H. A review of endothelial dysfunction in diabetes: a focus on the contribution of a dysfunctional eNOS. J. Am. Soc. Hypertens., 2010, 4, 102-115.
63. Grundy, S.M.; Howard, B.; Smith, S., Jr.; Eckel, R.; Redberg, R.; Bonow, R.O. Prevention Conference VI: Diabetes and Cardiovascular Disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation, 2002, 105, 2231-2239.
64. Rother, K.I. Diabetes treatment--bridging the divide. Ni. Engl. J Med., 2007, 356, 1499-1501.
65. Laight, D.W.; Carrier, M.J.; Anggard, E.E. Antioxidants, diabetes and endothelial dysfunction. Cardiovasc. Res., 2000, 47, 457-464.
66. Bohlen, H.G.; Lash, J.M. Topical hyperglycemia rapidly suppresses EDRF-mediated vasodilation of normal rat arterioles. Am. J. Physiol., 1993, 265, H219-225.
67. Meraji, S.; Jayakody, L.; Senaratne, M.P.; Thomson, A.B.; Kappagoda, T. Endothelium-dependent relaxation in aorta of BB rat. Diabetes, 1987, 36, 978-981.
68. Pieper, G.M.; Meier, D.A.; Hager, S.R. Endothelial dysfunction in a model of hyperglycemia and hyperinsulinemia. Am. J. Physiol., 1995, 269, H845-850.
69. Tesfamariam, B.; Brown, M.L.; Deykin, D.; Cohen, R.A. Elevated glucose promotes generation of endothelium-derived vasoconstrictor prostanoids in rabbit aorta. J. Clin. Invest., 1990, 85, 929-932.
70. Clarkson, P.; Celermajer, D.S.; Donald, A.E.; Sampson, M.; Sorensen, K.E.; Adams, M.; Yue, D.K.; Betteridge, D.J.; Deanfield, J.E. Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels. J. Am. Coll. Cardiol., 1996, 28, 573-579.
71. Johnstone, M.T.; Creager, S.J.; Scales, K.M.; Cusco, J.A.; Lee, B.K.; Creager, M.A. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation, 1993, 88, 2510-2516.
72. McVeigh, G.E.; Brennan, G.M.; Johnston, G.D.; McDermott, B.J.; McGrath, L.T.; Henry, W.R.; Andrews, J.W.; Hayes, J.R. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia, 1992, 35, 771-776.
73. Williams, S.B.; Cusco, J.A.; Roddy, M.A.; Johnstone, M.T.; Creager, M.A. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J. Am. Coll. Cardiol., 1996, 27, 567-574.
74. Du, X.L.; Edelstein, D.; Dimmeler, S.; Ju, Q.; Sui, C.; Brownlee, M. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J. Clin. Invest., 2001, 108, 1341-1348.
75. Okon, E.B.; Chung, A.W.; Rauniyar, P.; Padilla, E.; Tejerina, T.; McManus, B. M.; Luo, H.; van Breemen, C. Compromised arterial function in human type 2 diabetic patients. Diabetes, 2005, 54, 2415-2423.
76. Okumura, H.; Nagaya, N.; Itoh, T.; Okano, I.; Hino, J.; Mori, K.; Tsukamoto, Y.; Ishibashi-Ueda, H.; Miwa, S.; Tambara, K.; Toyokuni, S.; Yutani, C.; Kangawa, K. Adrenomedullin infusion attenuates myocardial ischemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway. Circulation, 2004, 109, 242-248.
77. Yang, S.; Lin, L.; Chen, J. X.; Lee, C.R.; Seubert, J.M.; Wang, Y.; Wang, H.; Chao, Z.R.; Tao, D.D.; Gong, J. P.; Lu, Z.Y.; Wang, D.W.; Zeldin, D.C. Cytochrome P-450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factoralpha via MAPK and PI3K/Akt signaling pathways. Am. J. Physiol. Heart Circ. Physiol., 2007, 293, H142-151.
78. Kawasaki, K.; Smith, R.S., Jr.; Hsieh, C.M.; Sun, J.; Chao, J.; Liao, J.K. Activation of the phosphatidylinositol 3-kinase/protein kinase Akt pathway mediates nitric oxide-induced endothelial cell migration and angiogenesis. Mol. Cell Biol., 2003, 23, 5726-5737.
79. Wang, Y.; Wei, X.; Xiao, X.; Hui, R.; Card, J.W.; Carey, M.A.; Wang, D.W.; Zeldin, D.C. Arachidonic acid epoxygenase metabolites stimulate endothelial cell growth and angiogenesis via mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways. J. Pharmacol. Exp. Ther., 2005, 314, 522-532.
80. Cook, S.; Hugli, O.; Egli, M.; Menard, B.; Thalmann, S.; Sartori, C.; Perrin, C.; Nicod, P.; Thorens, B.; Vollenweider, P.; Scherrer, U.; Burcelin, R. Partial gene deletion of endothelial nitric oxide synthase predisposes to exaggerated high-fat diet-induced insulin resistance and arterial hypertension. Diabetes, 2004, 53, 2067-2072.
81. Duplain, H.; Burcelin, R.; Sartori, C.; Cook, S.; Egli, M.; Lepori, M.; Vollenweider, P.; Pedrazzini, T.; Nicod, P.; Thorens, B.; Scherrer, U. Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation, 2001, 104, 342-345.
82. Shankar, R.R.; Wu, Y.; Shen, H.Q.; Zhu, J.S.; Baron, A.D. Mice with gene disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance. Diabetes, 2000, 49, 684-687.
83. Li, Y.; Lee, P. I. Controlled nitric oxide delivery platform based on S-nitrosothiol conjugated interpolymer complexes for diabetic wound healing. Mol Pharm, 2010, 7, 254-266.
84. Ahanchi, S.S.; Varu, V.N.; Tsihlis, N.D.; Martinez, J.; Pearce, C.G.; Kapadia, M.R.; Jiang, Q.; Saavedra, J. E.; Keefer, L.K.; Hrabie, J.A.; Kibbe, M.R. Heightened efficacy of nitric oxidebased therapies in type II diabetes mellitus and metabolic syndrome. Am. J. Physiol. Heart Circ. Physiol., 2008, 295, H2388-2398.
85. Pearce, C.G.; Najjar, S.F.; Kapadia, M.R.; Murar, J.; Eng, J.; Lyle, B.; Aalami, O.O.; Jiang, Q.; Hrabie, J. A.; Saavedra, J.E.; Keefer, L.K.; Kibbe, M.R. Beneficial effect of a short-acting NO donor for the prevention of neointimal hyperplasia. Free Radic. Biol. Med., 2008, 44, 73-81.
86. Nakagawa, T.; Sato, W.; Glushakova, O.; Heinig, M.; Clarke, T.; Campbell-Thompson, M.; Yuzawa, Y.; Atkinson, M. A.; Johnson, R. J.; Croker, B. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J. Am. Soc. Nephrol., 2007, 18, 539-550.
87. Molnar, J.; Yu, S.; Mzhavia, N.; Pau, C.; Chereshnev, I.; Dansky, H.M. Diabetes induces endothelial dysfunction but does not increase neointimal formation in high-fat diet fed C57BL/6J mice. Circ. Res., 2005, 96, 1178-1184.
88. Wann-Hansson, C.; Hallberg, I. R.; Risberg, B.; Lundell, A.; Klevsgard, R. Health-related quality of life after revascularization for peripheral arterial occlusive disease: long-term follow-up. J. Adv. Nurs., 2005, 51, 227-235.
89. Mikhailidis, D.P.; Elisaf, M.; Rizzo, M.; Berneis, K.; Griffin, B.; Zambon, A.; Athyros, V.; de Graaf, J.; Marz, W.; Parhofer, K.G.; Rini, G.B.; Spinas, G.A.; Tomkin, G.H.; Tselepis, A.D.; Wierzbicki, A.S.; Winkler, K.; Florentin, M.; Liberopoulos, E. "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr. Vasc. Pharmacol., 2011, 9, 533-571.
90. Mikhailidis, D.P.; Elisaf, M.; Rizzo, M.; Berneis, K.; Griffin, B.; Zambon, A.; Athyros, V.; de Graaf, J.; Marz, W.; Parhofer, K.G.; Rini, G.B.; Spinas, G.A.; Tomkin, G.H.; Tselepis, A.D.; Wierzbicki, A.S.; Winkler, K.; Florentin, M.; Liberopoulos, E. European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr. Vasc. Pharmacol., 2011, 9, 531-532.
91. Rizzo, M.; Kotur-Stevuljevic, J.; Berneis, K.; Spinas, G.; Rini, G.B.; Jelic-Ivanovic, Z.; Spasojevic-Kalimanovska, V.; Vekic, J. Atherogenic dyslipidemia and oxidative stress: a new look. Transl. Res., 2009, 153, 217-223.
92. Jialal, I.; Devaraj, S.; Venugopal, S.K. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension, 2004, 44, 6-11.
93. Pasceri, V.; Willerson, J.T.; Yeh, E.T. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation, 2000, 102, 2165-2168.
94. Venugopal, S.K.; Devaraj, S.; Yuhanna, I.; Shaul, P.; Jialal, I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation, 2002, 106, 1439-1441.
95. Kubes, P.; Suzuki, M.; Granger, D.N. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc. Natl. Acad. Sci. USA, 1991, 88, 4651-4655.
96. Zeiher, A.M.; Fisslthaler, B.; Schray-Utz, B.; Busse, R. Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. Circ. Res., 1995, 76, 980-986.
97. Aji, W.; Ravalli, S.; Szabolcs, M.; Jiang, X.C.; Sciacca, R.R.; Michler, R.E.; Cannon, P.J. L-arginine prevents xanthoma development and inhibits atherosclerosis in LDL receptor knockout mice. Circulation, 1997, 95, 430-437.
98. Boger, R.H.; Bode-Boger, S.M.; Brandes, R.P.; Phivthong-ngam, L.; Bohme, M.; Nafe, R.; Mugge, A.; Frolich, J.C. Dietary Larginine reduces the progression of atherosclerosis in cholesterolfed rabbits: comparison with lovastatin. Circulation, 1997, 96, 1282-1290.
99. Hattori, Y.; Hattori, S.; Wang, X.; Satoh, H.; Nakanishi, N.; Kasai, K. Oral administration of tetrahydrobiopterin slows the progression of atherosclerosis in apolipoprotein E-knockout mice. Arterioscler Thromb. Vasc. Biol., 2007, 27, 865-870.
100. Tiefenbacher, C.P.; Bleeke, T.; Vahl, C.; Amann, K.; Vogt, A.; Kubler, W. Endothelial dysfunction of coronary resistance arteries is improved by tetrahydrobiopterin in atherosclerosis. Circulation, 2000, 102, 2172-2179.
101. Wang, B.Y.; Candipan, R.C.; Arjomandi, M.; Hsiun, P.T.; Tsao, P.S.; Cooke, J.P. Arginine restores nitric oxide activity and inhibits monocyte accumulation after vascular injury in hypercholesterolemic rabbits. J. Am. Coll. Cardiol., 1996, 28, 1573-1579.
102. Kohnen, S. L.; Mouithys-Mickalad, A. A.; Deby-Dupont, G. P.; Deby, C. M.; Lamy, M. L.; Noels, A. F. Oxidation of tetrahydrobiopterin by peroxynitrite or oxoferryl species occurs by a radical pathway. Free Radic. Res., 2001, 35, 709-721.
103. Xu, J.; Xie, Z.; Reece, R.; Pimental, D.; Zou, M.H. Uncoupling of endothelial nitric oxidase synthase by hypochlorous acid: role of NAD(P)H oxidase-derived superoxide and peroxynitrite. Arterioscler. Thromb. Vasc. Biol., 2006, 26, 2688-2695.
104. Adams, M.R.; McCredie, R.; Jessup, W.; Robinson, J.; Sullivan, D.; Celermajer, D.S. Oral L-arginine improves endotheliumdependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease. Atherosclerosis, 1997, 129, 261-269.
105. Blum, A.; Hathaway, L.; Mincemoyer, R.; Schenke, W. H.; Kirby, M.; Csako, G.; Waclawiw, M. A.; Panza, J.A.; Cannon, R.O. 3rd Oral L-arginine in patients with coronary artery disease on medical management. Circulation, 2000, 101, 2160-2164.
106. Oomen, C.M.; van Erk, M.J.; Feskens, E.J.; Kok, F.J.; Kromhout, D. Arginine intake and risk of coronary heart disease mortality in elderly men. Arterioscler. Thromb. Vasc. Biol., 2000, 20, 2134-2139.
107. Kuzuya, M.; Nakamura, K.; Sasaki, T.; Cheng, X.W.; Itohara, S.; Iguchi, A. Effect of MMP-2 deficiency on atherosclerotic lesion formation in apoE-deficient mice. Arterioscler. Thromb. Vasc. Biol., 2006, 26, 1120-1125.
108. Eustace, B. K.; Jay, D.G. Extracellular roles for the molecular chaperone, hsp90. Cell Cycle, 2004, 3, 1098-1100.
109. Nakamura, T.; Hinagata, J.; Tanaka, T.; Imanishi, T.; Wada, Y.; Kodama, T.; Doi, T. HSP90, HSP70, and GAPDH directly interact with the cytoplasmic domain of macrophage scavenger receptors. Biochem. Biophys. Res. Commun., 2002, 290, 858-864.
110. Scherrer-Crosbie, M.; Ullrich, R.; Bloch, K.D.; Nakajima, H.; Nasseri, B.; Aretz, H.T.; Lindsey, M.L.; Vancon, A.C.; Huang, P.L.; Lee, R.T.; Zapol, W.M.; Picard, M.H. Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice. Circulation, 2001, 104, 1286-1291.
111. de Waard, M.C.; van der Velden, J.; Bito, V.; Ozdemir, S.; Biesmans, L.; Boontje, N.M.; Dekkers, D.H.; Schoonderwoerd, K.; Schuurbiers, H.C.; de Crom, R.; Stienen, G.J.; Sipido, K.R.; Lamers, J.M.; Duncker, D.J. Early exercise training normalizes myofilament function and attenuates left ventricular pump dysfunction in mice with a large myocardial infarction. Circ. Res., 2007, 100, 1079-1088.
112. de Waard, M.C.; van der Velden, J.; Boontje, N.M.; Dekkers, D.H.; van Haperen, R.; Kuster, D.W.; Lamers, J.M.; de Crom, R.; Duncker, D.J. Detrimental effect of combined exercise training and eNOS overexpression on cardiac function after myocardial infarction. Am. J. Physiol. Heart Circ. Physiol., 2009, 296, H1513-1523.
113. de Waard, M.C.; van Haperen, R.; Soullie, T.; Tempel, D.; de Crom, R.; Duncker, D.J. Beneficial effects of exercise training after myocardial infarction require full eNOS expression. J. Mol. Cell Cardiol., 2010, 48, 1041-1049.
114. Sessa, W.C.; Pritchard, K.; Seyedi, N.; Wang, J.; Hintze, T.H. Chronic exercise in dogs increases coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene expression. Circ. Res., 1994, 74, 349-353.
115. Shen, W.; Zhang, X.; Zhao, G.; Wolin, M. S.; Sessa, W.; Hintze, T.H. Nitric oxide production and NO synthase gene expression contribute to vascular regulation during exercise. Med. Sci. Sports Exerc., 1995, 27, 1125-1134.
116. Blair, S.N.; Kohl, H.W., 3rd; Barlow, C.E.; Paffenbarger, R.S., Jr.; Gibbons, L. W.; Macera, C.A. Changes in physical fitness and allcause mortality. A prospective study of healthy and unhealthy men. JAMA, 1995, 273, 1093-1098.
117. Ekelund, L.G.; Haskell, W.L.; Johnson, J.L.; Whaley, F.S.; Criqui, M.H.; Sheps, D.S. Physical fitness as a predictor of cardiovascular mortality in asymptomatic North American men. The Lipid Research Clinics Mortality Follow-up Study. N. Engl. J. Med., 1988, 319, 1379-1384.
118. Paffenbarger, R.S., Jr.; Hyde, R.T.; Wing, A.L.; Lee, I.M.; Jung, D.L.; Kampert, J.B. The association of changes in physical-activity level and other lifestyle characteristics with mortality among men. N. Engl. J. Med., 1993, 328, 538-545.
119. Wang, Y.; Wang, S.; Wier, W.G.; Zhang, Q.; Jiang, H.; Li, Q.; Chen, S.; Tian, Z.; Li, Y.; Yu, X.; Zhao, M.; Liu, J.; Yang, J.; Zhang, J.; Zang, W. Exercise improves the dilatation function of mesenteric arteries in postmyocardial infarction rats via a PI3K/Akt/eNOS pathway-mediated mechanism. Am. J. Physiol. Heart Circ. Physiol., 2010, 299, H2097-2106.
120. Widder, J.D.; Ertl, G. Exercise, eNOS and the heart after myocardial infarction. J. Mol. Cell Cardiol., 2010, 48, 1029-1030.
121. Dalkara, T.; Morikawa, E.; Panahian, N.; Moskowitz, M.A. Blood flow-dependent functional recovery in a rat model of focal cerebral ischemia. Am. J. Physiol., 1994, 267, H678-683.
122. Huang, Z.; Huang, P.L.; Ma, J.; Meng, W.; Ayata, C.; Fishman, M.C.; Moskowitz, M.A. Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine. J. Cereb. Blood Flow Metab., 1996, 16, 981-987.
123. Iadecola, C. Bright and dark sides of nitric oxide in ischemic brain injury. Trends Neurosci., 1997, 20, 132-139.
124. Samdani, A.F.; Dawson, T.M.; Dawson, V.L. Nitric oxide synthase in models of focal ischemia. Stroke, 1997, 28, 1283-1288.
125. Osuka, K.; Watanabe, Y.; Usuda, N.; Nakazawa, A.; Tokuda, M.; Yoshida, J. Modification of endothelial NO synthase through protein phosphorylation after forebrain cerebral ischemia/ reperfusion. Stroke, 2004, 35, 2582-2586.
126. Gaddam, K.K.; Verma, A.; Thompson, M.; Amin, R.; Ventura, H. Hypertension and cardiac failure in its various forms. Med. Clin. North Am., 2009, 93, 665-680.
127. Insull, W., Jr. The pathology of atherosclerosis: plaque development and plaque responses to medical treatment. Am. J. Med., 2009, 122, S3-S14.
128. Liapis, C.D.; Avgerinos, E.D.; Kadoglou, N.P.; Kakisis, J.D. What a vascular surgeon should know and do about atherosclerotic risk factors. J. Vasc. Surg., 2009, 49, 1348-1354.
129. Safar, M.E.; Jankowski, P. Central blood pressure and hypertension: role in cardiovascular risk assessment. Clin. Sci. (Lond), 2009, 116, 273-282.
130. Werner, C. M.; Bohm, M. The therapeutic role of RAS blockade in chronic heart failure. Ther. Adv. Cardiovasc. Dis., 2008, 2, 167-177.
131. Agabiti-Rosei, E. From macro-to microcirculation: benefits in hypertension and diabetes. J. Hypertens. Suppl., 2008, 26, S15-19.
132. Murphy, B.P.; Stanton, T.; Dunn, F.G. Hypertension and myocardial ischemia. Med. Clin. North Am., 2009, 93, 681-695.
133. Truong, L.D.; Shen, S.S.; Park, M.H.; Krishnan, B. Diagnosing nonneoplastic lesions in nephrectomy specimens. Arch. Pathol. Lab Med., 2009, 133, 189-200.
134. Tylicki, L.; Rutkowski, B. [Hypertensive nephropathy: pathogenesis, diagnosis and treatment]. Pol. Merkur. Lekarski., 2003, 14, 168-173.
135. Aronow, W.S. Hypertension and the older diabetic. Clin. Geriatr. Med., 2008, 24, 489-501, vi-vii.
136. Singer, D.R.; Kite, A. Management of hypertension in peripheral arterial disease: does the choice of drugs matter? Eur. J. Vasc. Endovasc. Surg., 2008, 35, 701-708.
137. Tracy, R.E.; White, S. A method for quantifying adrenocortical nodular hyperplasia at autopsy: some use of the method in illuminating hypertension and atherosclerosis. Ann. Diagn. Pathol., 2002, 6, 20-29.
138. Cahill, P.A.; Foster, C.; Redmond, E.M.; Gingalewski, C.; Wu, Y.; Sitzmann, J.V. Enhanced nitric oxide synthase activity in portal hypertensive rabbits. Hepatology, 1995, 22, 598-606.
139. Gardner, A.W.; Afaq, A. Management of lower extremity peripheral arterial disease. J. Cardiopulm. Rehabil. Prev., 2008, 28, 349-357.
140. Atochin, D.N.; Wang, A.; Liu, V.W.; Critchlow, J.D.; Dantas, A.P.; Looft-Wilson, R.; Murata, T.; Salomone, S.; Shin, H.K.; Ayata, C.; Moskowitz, M.A.; Michel, T.; Sessa, W.C.; Huang, P.L. The phosphorylation state of eNOS modulates vascular reactivity and outcome of cerebral ischemia in vivo. J. Clin. Invest., 2007, 117, 1961-1967.
141. Schmidt, T.S.; Alp, N.J. Mechanisms for the role of tetrahydrobiopterin in endothelial function and vascular disease. Clin. Sci. (Lond), 2007, 113, 47-63.
142. Cosentino, F.; Patton, S.; d'Uscio, L.V.; Werner, E.R.; Werner-Felmayer, G.; Moreau, P.; Malinski, T.; Luscher, T.F. Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats. J. Clin. Invest., 1998, 101, 1530-1537.
143. Hong, H.J.; Hsiao, G.; Cheng, T.H.; Yen, M.H. Supplemention with tetrahydrobiopterin suppresses the development of hypertension in spontaneously hypertensive rats. Hypertension, 2001, 38, 1044-1048.
144. Kase, H.; Hashikabe, Y.; Uchida, K.; Nakanishi, N.; Hattori, Y. Supplementation with tetrahydrobiopterin prevents the cardiovascular effects of angiotensin II-induced oxidative and nitrosative stress. J. Hypertens, 2005, 23, 1375-1382.
145. Cosentino, F.; Barker, J.E.; Brand, M.P.; Heales, S.J.; Werner, E.R.; Tippins, J.R.; West, N.; Channon, K. M.; Volpe, M.; Luscher, T.F. Reactive oxygen species mediate endothelium-dependent relaxations in tetrahydrobiopterin-deficient mice. Arterioscler. Thromb. Vasc. Biol., 2001, 21, 496-502.
146. Nandi, M.; Miller, A.; Stidwill, R.; Jacques, T.S.; Lam, A.A.; Haworth, S.; Heales, S.; Vallance, P. Pulmonary hypertension in a GTP-cyclohydrolase 1-deficient mouse. Circulation, 2005, 111, 2086-2090.
147. Michel, T.; Vanhoutte, P. M. Cellular signaling and NO production. Pflugers Arch, 2010, 459, 807-816.